Melzer, T. R., Stark, M. R., Keenan, R. J., Myall, D. J., MacAskill, M. R., Pitcher, T. L., . . . Anderson, T. J. (2019). Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease. FRONTIERS IN NEUROLOGY, 10, ARTN 391. doi:10.3389/fneur.2019.00391

Uccelli, A., Laroni, A., Brundin, L., Clanet, M., Fernandez, O., Nabavi, S. M., . . . Karimi, S. (2019). MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): A randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials, 20 (1). doi:10.1186/s13063-019-3346-z

Ciccarelli, O., Cohen, J. A., Reingold, S. C., Weinshenker, G., & on behalf of the participants at the International Conference on Spinal Cord Involvement & Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. (2019). Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology. doi:10.1016/S1474-4422(18)30460-5

Gold, J., Marta, M., Meier, U. C., Christensen, T., Miller, D., Altmann, D., . . . Giovannoni, G. (2018). A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study. Multiple Sclerosis and Related Disorders, 24, 123-128. doi:10.1016/j.msard.2018.06.002

Miller, D. H., Lublin, F. D., Sormani, M. P., Kappos, L., Yaldizli, Ö., Freedman, M. S., . . . Wolinsky, J. S. (2018). Brain atrophy and disability worsening in primary progressive multiple sclerosis: Insights from the INFORMS study. Annals of Clinical and Translational Neurology. doi:10.1002/acn3.534

Ontaneda, D., Tallantyre, E., Nakamura, K., Planchon, S. M., Miller, D. M., Hersh, C., . . . Evangelou, N. (2018). Design and rationale of the determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis (DELIVER-MS) trial. Presented at: 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS).

Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., . . . Cohen, J. A. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology, 17 (2), 162-173. doi:10.1016/S1474-4422(17)30470-2

Montalban, X., Gold, R., Thompson, A. J., Otero-Romero, S., Amato, M. P., Chandraratna, D., . . . Zipp, F. (2018). ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. European Journal of Neurology, 25 (2), 215-237. doi:10.1111/ene.13536

Montalban, X., Gold, R., Thompson, A. J., Otero-Romero, S., Amato, M. P., Chandraratna, D., . . . Zipp, F. (2018). ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 24 (2), 96-120. doi:10.1177/1352458517751049

Amato, M. P., Derfuss, T., Hemmer, B., Liblau, R., Montalban, X., Sorensen, P. S., & Miller, D. H. (2018). Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. MULTIPLE SCLEROSIS JOURNAL, 24 (5), 590-603. doi:10.1177/1352458516686847